Biomarker Services
Customised biomarker panels to enhance all stages of therapeutic development
Innovative Biomarker Analysis Solutions
Synexa Life Sciences has over two decades experience designing biomarker strategies to support customers’ broader clinical development objectives. Our team of scientists are experts in developing optimum biomarker strategies for biomarker discovery, selection and analysis in order to meet your clinical development goals.
Synexa’s global setup aims to support research programs from translational research through to late-stage clinical trials and post-marketing surveillance. Working collaboratively, we focus on careful selection of markers to ensure results that support decision-making and progression through the therapeutic pipeline with confidence.
 
															Specialised Biomarker Services
Biomarker Consultation
Advice on the optimal selection of biomarkers in the context of the drug, disease and budget.
 
															Biomarker Assay Development & Validation
Development, optimisation and validation of biomarker assays across a wide range of matrices and technology platforms.
 
															Biomarker Analysis
Biomarker analysis of clinical samples for exploratory or clinical trial settings.
Biomarker Solutions
Comprehensive biomarker solutions, from biomarker discovery through to selection and biomarker assay development
 
															Protein
- AlphaLISA
- CBA
- DELFIA
- ELISA & ELISpot
- Fluorescence and luminescence-based assays
- Gyrolab
- MesoScale
- Nephelometry
- Olink
- Radioimmunoassays
 
															DNA
- Digital PCR (dPCR)
- Electrophoresis
- Pharmacogenetics
- Targeted Sequencing
 
															RNA
- Gene expression array
- NanoString
- RT-qPCR
 
															Cell
- Cell Culture Assays
- Circulating Tumor Cells (CTC)
- Flow Cytometry
- ELISpot
- FluoroSpot
- Fluorescence Microscopy
- Microbiology
- Sorting
 
															Tissue
- Correlative Light and Electron Microscopy (CLEM)
- Multiplex Immunofluorescence
- Organotypic culture
- Super Resolution Microscopy
- Whole Tissue Analysis
Biomarker Platforms
Our technology platforms are robust, reliable and reputable in the clinical field and provide comprehensive and detailed data readouts for your application.
 
															VICTOR® Nivo™
 
															Waters T-QS LC-MS/MS
 
															Sciex 6500+
 
															Waters Premier I-Class UPLC
 
															BD FacsLyric (12 colours)
 
															MSD S600
 
															MSD SQ 120
 
															Olink Signature q100
 
															WIZARD2 gammacounter
 
															Biacore T200 GxP SPR
 
															Envision Xcite
 
															Gyrolab xPlore
FAQ
					 What guidelines does Synexa use to validate biomarker assays? 
							
			
			
		
						
				None; Synexa’s biomarker assays are validated as fit for purpose based on their context of use.
					 Does Synexa offer pre-validated biomarker assays? 
							
			
			
		
						
				Whilst Synexa specialises in the development of complex and custom-designed assays, Synexa does offer pre-validated biomarker assays – depending on the context of use, sample type and duration of the study.
					 What makes Synexa Life Sciences biomarker specialists? 
							
			
			
		
						
				BM analysis often requires flexible thinking and delivery to allow for pre-analyical stability considerations, complex data interpretations and outputs and fit for purpose validations. Our experince allows for this and more, providing quality data without the rigidity of PK workflows.
					 Can Synexa measure low-abundance biomarkers, such as cytokines with low fg-pg/mL ranges? 
							
			
			
		
						
				Yes, we recommend using MSD’s S-PLEX ultrasensitive assay platform for the measurement of analytes at extremely low concentrations or to reduce required sample volume / critical reagent usage.
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
 
															